Skip to content

Free Nonvascularized Fibula Autograft for Tumor-like Lesions in Femoral Neck Using in Pediatric Patients

Yulin Orthopedics Hospital of Chinese and Western Medicine

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03129230
Enrollment
16
Registered
2017-04-26
Start date
2012-08-01
Completion date
2017-03-01
Last updated
2018-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Diseases

Brief summary

This study was to evaluate the safety and efficacy of free nonvascularized fibula autograft in the treatment of the femoral neck tumor-like lesions before epiphyseal closure in pediatric patients, by presenting the clinic-radiological outcome and complications.

Interventions

PROCEDUREfree nonvascularized fibula autograft

Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.

Sponsors

Yulin Orthopedics Hospital of Chinese and Western Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
7 Years to 13 Years
Healthy volunteers
No

Inclusion criteria

1\. This retrospective study included pediatric patients before epiphyseal closure with tumor-like lesions in femoral neck.

Exclusion criteria

1. pediatric patients with tumor-like lesions in femoral neck after epiphyseal closure; 2. pediatric patients with benign bone tumors and malignant bone tumors in the femoral neck after epiphyseal closure; 3. adult patients with benign or malignant bone tumors and tumor-like lesions in femoral neck.

Design outcomes

Primary

MeasureTime frameDescription
change of peri-implant bone level from baseline at 7 and 54 months7 months to 54 monthsMean follow-up of all the patients after primary surgery was 24 months, ranged 7 months to 54 months.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026